Alebund Pharmaceuticals (Jiangsu) Ltd. saw its shares more than double on their trading debut in Hong Kong, driven by investor enthusiasm for its renal disease drug pipeline and existing revenue stream. The stock opened 85.84% higher and closed at HK$46, a rise of 103.54%, significantly outperforming the average first-day gain of 72.72% seen by other biotech listings this year. The strong market reception underscores confidence in the company's strategy to commercialize treatments for chronic kidney disease, a condition affecting 124 million people in China.

The initial public offering (IPO) was priced at HK$22.60 per share, with a lot size of 100 shares and a minimum investment of nearly HK$2,283. The offering involved 56.76 million shares, representing 16.70% of the firm’s overall share capital, and generated projected gross proceeds of about HK$1.28 billion ($164 million). Demand was robust, with the issue oversubscribed by approximately 963 times and a one-lot success rate of just 6%.

Financial Performance and Backing

Despite the successful listing, Alebund remains unprofitable due to heavy research and development expenditures. The company reported losses of 335 million yuan ($49 million) in 2024 and 752 million yuan in 2025. R&D spending reached 235 million yuan and 373 million yuan for those respective years. However, unlike many pre-profit biotechs, Alebund has established an income stream through a 2023 deal to license Roche's anemia drug, Mircera, for mainland China. Revenue from this drug jumped 368% in 2025 to about 30.6 million yuan after it was included in China’s health insurance coverage.

The IPO secured significant institutional support, with 11 cornerstone investors subscribing for about $81.5 million in shares, representing 49.78% of the global offering. Notable backers include Tencent Holdings, GIC, Loomis Sayles, and GF Fund Management. Prior to the IPO, Alebund raised around 2 billion yuan in multiple financing rounds from investors such as Lilly Asia Ventures and Loyal Valley Capital.

Pipeline and Strategic Focus

Alebund's core product, AP301, is an oral phosphate binder designed to treat high phosphate levels in the blood resulting from renal disease. The company was due to submit a new drug application in China for AP301 in June. The product is currently in Phase Three multi-regional trials in the United States and China. Management has prioritized the commercialization of AP301, predicting Chinese approval in 2027 and a U.S. launch in 2029.

The company is also developing AP306, an oral pan-phosphate transporter inhibitor for hyperphosphatemia. Phase Two B global trials for AP306 began in May and are scheduled to complete in the second quarter of 2027. Alebund entered a partnership with U.S.-based R1 Therapeutics last year to develop this treatment overseas. Following its debut, Alebund commands a market value of about HK$15.6 billion, a premium compared to Everest Medicines, which has a market value of HK$8.5 billion.